Enzo Biochem's (ENZ) PLAQPRO Lp-PLA2 Assay Approved by New York Dept. of Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Enzo Biochem Announces New York State Health Department Approval of New Easily Adaptable, Cost Effective Cardiac Assay
September 20, 2016 12:24 PM EDTPLAQPRO Lp-PLA2 Assay is Based on a Proprietary Enzo Biochem Assay Platform, Further Underscoring Growing Importance of Companys Clinically Relevant Diagnostics
NEW YORK--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE: ENZ) today announced that the New York State Department of Health has granted conditional approval for use of Enzo Clinical Labs PLAQPRO Lp-PLA2 Assay.
This cardiac assay delivers improved consistency and is designed to work on open platform clinical analysis instruments. The open platform configuration is one of the several factors that... More
